IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Comparison of Efficacy and Tolerability of Cinnarizine with Betahistine in the Treatment of Otogenic Vertigo

Author: UPLOADED BY-ADMIN, RAVITEJA BODLA, PRASAD THOTA, AJAYKUMAR SARABU, MOHANTHA GP, RUTA HANMUGAM
Abstract: Peripheral vestibular disorders frequently lead to the manifestation of symptoms of vertigo. The objective of this study was to compare the efficacy and tolerability of Cinnarizine 25mg with Betahistine 16mg in the treatment of otogenic vertigo. Eighty patients with vertigo due to otogenic origin participated in this prospective, comparative, single-centre study. Patients were randomly allocated to treatment with Betahistine 16mg or Cinnarizine 25mg, given three times daily for 4 weeks. Efficacy was determined by assessments of vertigo symptoms after 1 and 4 weeks of treatment using a visual analogue scale to determine 'mean vertigo score'. Treatment with Betahistine led to significantly greater improvements in mean vertigo scores compared with Cinnarizine. This was evident as early as 1 week after the onset of treatment (p = 0.002). After 4 weeks, Betahistine decreased the intensity of vertigo symptoms about 2-fold compared with Cinnarizine (p = 0.001). Reductions in symptoms typically associated with vertigo were more pronounced (p = 0.009) in Betahistine group compared with Cinnarizine group after 4 weeks of treatment. No serious adverse events were reported in either treatment group. Tolerability of the Betahistine was judged as 'very good' by 90% (Cinnarizine 97%) and as 'good' by 10% (Cinnarizine 3%). Betahistine was shown to be effective and very well tolerated treatment option for patients with otogenic vertigo. It proved to be statistically more efficient in reducing vertigo than Cinnarizine. Therefore, Betahistine may be considered first-line treatment option for the treatment of otogenic vertigo.
Keyword: Otogenic vertigo, vestibular disorders, cinnarizine, betahistine
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free